In this expert panel, investors and senior directors go for growth over exits and explore value creation in the long game. They will wrestle with what “build-to-last” means in biotech – once again moving on the conversation beyond the 10-year LP fund, and explore the financial and partnering strategy required from the starting-point to safeguard your shot at building a mid-sized biotech, and taking your drugs to market.
Read more...